Ubs Group Ag Crispr Therapeutics Ag Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Ubs Group Ag holds 20,314 shares of CRSP stock, worth $827,186. This represents 0.0% of its overall portfolio holdings.

Number of Shares

20,314

Previous 424,216 95.21%

Holding current value

$827,186

Previous $22.9 Million 95.84%

% of portfolio

0.0%

Previous 0.01%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$44.62 - $62.75 $11.1 Million - $15.6 Million	249,372 Added 58.78%	673,588 $31.7 Million
Q2 2024 Aug 13, 2024	BUY	$51.17 - $68.18 $5.31 Million - $7.08 Million	103,839 Added 32.41%	424,216 $22.9 Million
Q1 2024 May 13, 2024	BUY	$60.67 - $89.12 $574,666 - $844,144	9,472 Added 3.05%	320,377 $21.8 Million
Q4 2023 Feb 09, 2024	SELL	$38.62 - $72.18 $1.01 Million - $1.89 Million	-26,225 Reduced 7.78%	310,905 $19.5 Million
Q3 2023 Nov 09, 2023	BUY	$45.39 - $59.0 $3.38 Million - $4.39 Million	74,470 Added 28.35%	337,130 $15.3 Million
Q2 2023 Aug 11, 2023	BUY	$43.47 - $67.77 $774,070 - $1.21 Million	17,807 Added 7.27%	262,660 $14.7 Million
Q1 2023 May 12, 2023	SELL	$41.0 - $56.12 $8.35 Million - $11.4 Million	-203,682 Reduced 45.41%	244,853 $11.1 Million
Q4 2022 Feb 08, 2023	BUY	$39.19 - $65.67 $7.08 Million - $11.9 Million	180,573 Added 67.39%	448,535 $18.2 Million
Q3 2022 Nov 10, 2022	BUY	$61.1 - $83.78 $2.08 Million - $2.85 Million	34,043 Added 14.55%	267,962 $17.5 Million
Q2 2022 Aug 10, 2022	BUY	$43.23 - $73.83 $1.32 Million - $2.25 Million	30,487 Added 14.99%	233,919 $14.2 Million
Q1 2022 May 16, 2022	BUY	$53.19 - $79.24 $720,298 - $1.07 Million	13,542 Added 7.13%	203,432 $12.8 Million
Q4 2021 Feb 14, 2022	BUY	$70.09 - $111.29 $3.52 Million - $5.59 Million	50,237 Added 35.97%	189,890 $14.4 Million
Q3 2021 Nov 15, 2021	BUY	$110.2 - $156.64 $2.63 Million - $3.74 Million	23,879 Added 20.63%	139,653 $15.6 Million
Q2 2021 Aug 13, 2021	SELL	$100.84 - $161.89 $12.3 Million - $19.8 Million	-122,105 Reduced 51.33%	115,774 $18.7 Million
Q1 2021 May 12, 2021	BUY	$110.72 - $210.04 $11.4 Million - $21.6 Million	102,618 Added 75.87%	237,879 $29 Million
Q4 2020 Feb 11, 2021	BUY	$79.67 - $173.23 $3.35 Million - $7.29 Million	42,068 Added 45.14%	135,261 $20.7 Million
Q3 2020 Nov 12, 2020	BUY	$78.5 - $100.64 $690,721 - $885,531	8,799 Added 10.43%	93,193 $7.8 Million
Q2 2020 Jul 31, 2020	BUY	$38.5 - $76.05 $610,148 - $1.21 Million	15,848 Added 23.12%	84,394 $6.2 Million
Q1 2020 May 01, 2020	BUY	$33.68 - $62.53 $409,313 - $759,927	12,153 Added 21.55%	68,546 $2.91 Million
Q4 2019 Feb 14, 2020	BUY	$36.68 - $73.13 $401,132 - $799,749	10,936 Added 24.06%	56,393 $3.44 Million
Q3 2019 Nov 14, 2019	SELL	$40.99 - $52.56 $471,671 - $604,807	-11,507 Reduced 20.2%	45,457 $1.86 Million
Q2 2019 Aug 14, 2019	BUY	$35.45 - $48.2 $20,206 - $27,474	570 Added 1.01%	56,964 $2.68 Million
Q1 2019 May 14, 2019	BUY	$28.02 - $40.87 $151,308 - $220,698	5,400 Added 10.59%	56,394 $2.02 Million
Q4 2018 Feb 14, 2019	SELL	$22.73 - $42.34 $694,628 - $1.29 Million	-30,560 Reduced 37.47%	50,994 $1.46 Million
Q3 2018 Nov 14, 2018	SELL	$44.35 - $65.71 $43,063 - $63,804	-971 Reduced 1.18%	81,554 $3.62 Million
Q2 2018 Aug 14, 2018	BUY	$42.62 - $73.59 $985,800 - $1.7 Million	23,130 Added 38.94%	82,525 $4.85 Million
Q1 2018 May 15, 2018	BUY	$23.52 - $58.17 $1.34 Million - $3.32 Million	57,025 Added 2406.12%	59,395 $2.72 Million
Q4 2017 Feb 14, 2018	BUY	$16.95 - $23.48 $30,510 - $42,264	1,800 Added 315.79%	2,370 $56,000
Q3 2017 Nov 14, 2017	SELL	$16.75 - $20.66 $16,046 - $19,792	-958 Reduced 62.7%	570 $10,000
Q2 2017 Aug 14, 2017	BUY	N/A	958 Added 168.07%	1,528 $25,000
Q1 2017 Nov 14, 2017	BUY	N/A	570	570 $12,000

Others Institutions Holding CRSP

# of Institutions

490

Shares Held

58M

Call Options Held

1.1M

Put Options Held

1.9M

View Full List

About CRISPR Therapeutics AG

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.18B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

More about CRSP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account